Head and Neck Cancer Trial Completes Enrollment

Share this article:

(ChemotherapyAdvisor) – A treatment for head and neck cancer is now on its way into Phase 3 clinical trials. Oncolytics Biotech Inc. announced today that it has completed enrollment in the first stage of its Phase 3 clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

The comparative assessment of intravenous administration of REOLYSIN with the chemotherapy combination of paclitaxel and carboplatin versus the chemotherapy alone will take place in patients with metastatic or recurrent squamous cell carcinoma of the head and neck, or squamous cell cancer of the nasopharynx, who have progressed while (or after) receiving prior platinum-based chemotherapy.

In this randomized, two-arm, double-blind, multicenter, two-stage, adaptive trial, all patients will receive treatment every three weeks (21-day cycles) with paclitaxel and carboplatin, and will also receive, on a blinded basis, either intravenous placebo or intravenous REOLYSIN. All dosing takes place in the first five days of each cycle, with all patients receiving standard intravenous doses of paclitaxel and carboplatin on day one only, and on days one through five, either intravenous placebo or intravenous REOLYSIN.

The trial must meet the primary endpoint of overall survival (OS). The trial has just completed enrollment for the first, or non-adaptive, stage, which is designed to enroll 80 patients. The next stage will be adaptive and is designed to enroll between 100 and 400 patients.

The multicenter trial will be conducted at more than 80 centers in 12 countries in North America and Europe, including the U.S.

Press Release

Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Next Article in Head and Neck Cancer

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Head and Neck Cancer

Valproic Acid Cut Head, Neck Cancer Risk

Valproic Acid Cut Head, Neck Cancer Risk

No differences in cancer incidence with VPA use for cancers of the lung, bladder, colon or prostate.

FDA to Review Lymphoseek sNDA in Head and Neck Cancer

FDA to Review Lymphoseek sNDA in Head and ...

The FDA has accepted the Supplemental New Drug Application and granted it Priority Review for the expanded use of Lymphoseek Injection for sentinel lymph node detection in patients with head ...

Oropharyngeal Cancer Incidence Is Increasing

Oropharyngeal Cancer Incidence Is Increasing

From 1973 to 2009, the incidence of oropharyngeal squamous cell carcinoma (OPSCC) increased in patients younger than 45 years.